Search the Newsreel

BioLife Solutions (NASDAQ:BLFS) Stock Rating Lowered by Wall Street Zen

BioLife Solutions (BLFS) Faces Fairness Probes After Repligen Agrees To Buy It

BioLife Solutions (BLFS) is facing fairness probes from several law firms after Repligen agreed to acquire the company. The investigations focus on ensuring the transaction terms are fair to BioLife Solutions shareholders, considering the agreed US$31.00 per share price which includes a mix of …

BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). KSF is concerned that the offered consideration of $11.25 in cash and 0.1442 shares of Repligen common stock per BioLife share may …

Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-and-stock deal

Repligen is acquiring BioLife Solutions (BLFS) in a cash-and-stock deal valued at approximately $1.5 billion, with BioLife shareholders receiving $11.25 cash and 0.1442 Repligen shares per BioLife share. The acquisition aims to strengthen Repligen's position in the rapidly growing cell therapy market, leveraging BioLife's …

What is HC Wainwright's Estimate for BLFS Q1 Earnings?

BIOLIFE SOLUTIONS INC : JEFFERIES CUTS TO HOLD FROM BUY; RAISES TARGET PRICE TO $31 FROM $30

Jefferies has changed its rating for Biolife Solutions Inc. (BLFS.O) from "buy" to "hold." Despite the downgrade, the investment bank increased its target price for the company's stock to $31 from its previous estimate of $30. This adjustment reflects a nuanced view from Jefferies …

BioLife Solutions to be acquired by Repligen in $1.5B cell therapy deal

BioLife Solutions, a Bothell, Wash.-based company specializing in tools for cell and gene therapy, is set to be acquired by Repligen, a life sciences corporation, for $1.5 billion. The deal involves BioLife shareholders receiving $11.25 in cash plus 0.1442 shares of Repligen stock per …

BioLife Solutions Inc

Repligen Corp announced its intent to acquire BioLife Solutions in a cash-and-stock deal valued at approximately $1.5 billion. This acquisition is aimed at expanding Repligen's presence in the rapidly growing cell therapy market. The deal positions Repligen to capitalize on the increasing demand for …

Goodwin Advises Repligen In Acquisition Of BioLife Solutions For Approximately $1.5 Billion

Goodwin Procter LLP advised Repligen Corporation in its definitive agreement to acquire BioLife Solutions, Inc., for approximately $1.5 billion. The transaction, comprising 64% Repligen common stock and 36% cash, has been unanimously approved by both companies' directors and is expected to close in the …

BioLife Solutions Inc (BLFS) Stock Up 6.8% but GF Value Says Overvalued -- GF Score: 72/100

BioLife Solutions Inc (BLFS) shares recently rose 6.8% to $31.15, trading near its 52-week high. However, GuruFocus's GF Value™ indicates the stock is 7.7% overvalued at $28.93, with a high historical P/E ratio. Despite an above-average GF Score™ of 72/100, insider selling of $28.1 …

BioLife Solutions to Be Acquired by Repligen for $11.25 Cash Plus 0.1442 Share Per Share

BioLife Solutions has agreed to be acquired by Repligen in a definitive merger agreement. Repligen will pay $11.25 in cash plus 0.1442 shares of Repligen common stock for each outstanding BioLife share. The acquisition is expected to close in the fourth quarter of 2026, …

Repligen Corporation entered into an agreement and plan of merger to acquire BioLife Solutions, Inc. for approximately $1.6 billion.

Repligen Corporation has agreed to acquire BioLife Solutions, Inc. for approximately $1.6 billion in a cash and stock deal. BioLife stockholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stock, totaling $31.00 per share. The acquisition is expected to …

Shareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating BioLife Solutions, Inc. (NASDAQ: BLFS) regarding a potential breach of fiduciary duty concerning its transaction with Repligen. BioLife shareholders are set to receive $11.25 in cash and 0.1442 shares of Repligen stock, totaling $31.00 per share, valuing the deal at …

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS)

Monteverde & Associates PC, a class action firm, has launched an investigation into BioLife Solutions, Inc. (NASDAQ: BLFS) regarding its proposed sale to Repligen Corporation. Shareholders are expected to receive $11.25 in cash and 0.1442 shares of Repligen stock per share. The firm is …

Press Release: Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities With Market Leading Biopreservation Media

Repligen Corporation is set to acquire BioLife Solutions to enhance its cell therapy capabilities through BioLife's biopreservation media. This strategic acquisition aims to strengthen Repligen's position in the cell and gene therapy market by integrating BioLife's market-leading solutions. The move comes as demand for …

Repligen buys BioLife Solutions for $1.5 billion

Repligen has agreed to acquire BioLife Solutions in a cash-and-stock transaction valued at approximately $1.5 billion, with BioLife investors set to receive $31 per share. Repligen expects this acquisition to bolster revenue growth, margins, and adjusted earnings, while committing to at least $20 million …

Form 4 BioLife Solutions Inc For: 21 July By Investing.com

This article reports on a Form 4 filing for BioLife Solutions Inc. on July 21st, as published by Investing.com. It is a brief news item indicating an insider transaction or change in beneficial ownership for the company. The article provides the company's stock symbol …

BioLife Solutions (NASDAQ: BLFS) CTO has 275 shares withheld for RSU taxes

BioLife Solutions Inc.'s Chief Technology Officer, Sean Werner, had 275 shares of Common Stock withheld by the company on July 17, 2026, to cover tax obligations related to the release of his restricted stock units. The shares were withheld at a price of $29.15 …

Biolife Solutions stock hits 52-week high at 30.03 USD

BioLife Solutions Inc. (BLFS) shares reached a new 52-week high of $30.03, currently trading at $29.92. The stock has seen significant growth, with a 38.52% increase over the past year and impressive revenue growth of nearly 30% in the last twelve months. This performance …

BLFS Forecast — Price Target — Prediction for 2027

BioLife Solutions Reports First Quarter 2026 Financial Results

Earnings call transcript: BioLife Solutions Q1 2026: Revenue Surges, Stock Rises

BioLife Solutions, Inc. (BLFS) Tops Q1 Earnings and Revenue Estimates

BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations

BioLife Solutions Updates Earnings Call Information | BLFS Stock News